[{"id":"e9745708-7929-4504-9e2d-4c705c19fc86","acronym":"","url":"https://clinicaltrials.gov/study/NCT03611556","created_at":"2023-10-04T01:11:28.511Z","updated_at":"2024-07-02T16:35:34.886Z","phase":"Phase 1b/2","brief_title":"MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.","source_id_and_acronym":"NCT03611556","lead_sponsor":"MedImmune LLC","biomarkers":" NT5E","pipe":" | ","alterations":" CD73 expression","tags":["NT5E"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 07/22/2022","primary_completion_date":" 07/22/2022","study_txt":" Completion: 07/22/2022","study_completion_date":" 07/22/2022","last_update_posted":"2023-10-03"},{"id":"ed45cc8a-5b1f-4212-bf7f-555eb5b9a4a1","acronym":"LUNGadenosine","url":"https://clinicaltrials.gov/study/NCT05648188","created_at":"2022-12-13T14:58:00.644Z","updated_at":"2024-07-02T16:35:59.218Z","phase":"","brief_title":"A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells","source_id_and_acronym":"NCT05648188 - LUNGadenosine","lead_sponsor":"Centre Hospitalier Universitaire de Nice","biomarkers":" NT5E • ENTPD1","pipe":" | ","alterations":" CD73 expression • ENTPD1 expression","tags":["NT5E • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression • ENTPD1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2022-12-13"}]